1. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
- Author
-
Iyer, Janani S, Juyal, Dinkar, Le, Quang, Shanis, Zahil, Pokkalla, Harsha, Pouryahya, Maryam, Pedawi, Aryan, Stanford-Moore, S Adam, Biddle-Snead, Charles, Carrasco-Zevallos, Oscar, Lin, Mary, Egger, Robert, Hoffman, Sara, Elliott, Hunter, Leidal, Kenneth, Myers, Robert P, Chung, Chuhan, Billin, Andrew N, Watkins, Timothy R, Patterson, Scott D, Resnick, Murray, Wack, Katy, Glickman, Jon, Burt, Alastair D, Loomba, Rohit, Sanyal, Arun J, Glass, Ben, Montalto, Michael C, Taylor-Weiner, Amaro, Wapinski, Ilan, and Beck, Andrew H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,6.1 Pharmaceuticals ,Oral and gastrointestinal ,Humans ,Artificial Intelligence ,Clinical Trials as Topic ,Non-alcoholic Fatty Liver Disease ,Liver Cirrhosis ,Patient Selection ,Endpoint Determination ,Female ,Retrospective Studies ,Male ,Automation ,Liver Diseases ,Reproducibility of Results ,Medical and Health Sciences ,Immunology ,Biomedical and clinical sciences ,Health sciences - Abstract
Clinical trials in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria and endpoints. However, variability in interpretation has impacted clinical trial outcomes. We developed an artificial intelligence-based measurement (AIM) tool for scoring MASH histology (AIM-MASH). AIM-MASH predictions for MASH Clinical Research Network necroinflammation grades and fibrosis stages were reproducible (κ = 1) and aligned with expert pathologist consensus scores (κ = 0.62-0.74). The AIM-MASH versus consensus agreements were comparable to average pathologists for MASH Clinical Research Network scores (82% versus 81%) and fibrosis (97% versus 96%). Continuous scores produced by AIM-MASH for key histological features of MASH correlated with mean pathologist scores and noninvasive biomarkers and strongly predicted progression-free survival in patients with stage 3 (P
- Published
- 2024